ArticlePloS one2025
Optical coherence tomography analysis at initial diagnosis in patients with retinitis pigmentosa and associated cystoid macular edema.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study analyzed optical coherence tomography (OCT) findings in 130 eyes of 130 patients with retinitis pigmentosa (RP) at initial diagnosis, including 42 with cystoid macular edema (CME) and 88 without, between September 2016 and March 2024. The CME group exhibited increased central macular thickness (CMT) (257.50 ± 104.98 µm vs. 171.40 ± 73.15 µm, p = 0.000), whereas the non-CME group had greater subfoveal choroidal thickness (SCT) (294.52 ± 122.85 µm vs. 246.98 ± 87.31 µm, p = 0.043), total choroidal area (TCA) (4.64 ± 1.98 mm² vs. 3.82 ± 1.34 mm², p = 0.031), stromal area (SA) (1.85 ± 0.76 mm² vs. 1.53 ± 0.54 mm², p = 0.025), luminal area (LA) (2.79 ± 1.22 mm² vs. 2.30 ± 0.81 mm², p = 0.033), and foveal avascular zone in the superficial capillary plexus (FAZ_SCP) (0.42 ± 0.31 mm² vs. 0.27 ± 0.12 mm², p = 0.022). The CME group had more moderate stage cases (47.62% vs. 26.14%, p = 0.015), while the non-CME group had more advanced cases (39.77% vs. 9.52%, p = 0.000). Visual acuity (logMAR) worsened in advanced stages for both groups (CME: 1.62 ± 0.79, p = 0.003; Non-CME: 1.12 ± 0.80, p = 0.000). In the CME group, FAZ in the deep capillary plexus (FAZ_DCP) enlarged from moderate to advanced stages (0.28 ± 0.12 mm² to 0.64 ± 0.09 mm², p = 0.025), and vessel density in the deep capillary plexus (VD_DCP) decreased from early to moderate stages (31.83 ± 3.94% to 28.75 ± 2.71%, p = 0.036), whereas superficial capillary plexus vessel density (VD_SCP) remained stable across stages (early: 32.82 ± 2.59%, moderate: 31.04 ± 2.37%, advanced: 31.52 ± 1.26%, all p > 0.1). The non-CME group exhibited progressive declines in CMT (early: 226.27 ± 38.60 µm, moderate: 195.04 ± 52.56 µm, advanced: 108.83 ± 59.72 µm, all p < 0.01) and choroidal vascularity index (CVI) (early: 0.61 ± 0.02, moderate: 0.60 ± 0.02, advanced: 0.58 ± 0.04, all p < 0.05). In the CME group, visual acuity (logMAR) was positively correlated with cyst area (p = 0.019, rho = 0.361) and FAZ_DCP (p = 0.002, rho = 0.564). These findings suggest that RP-CME may be associated with choroidal atrophy regardless of disease stage and could have a compensatory mechanism to SCP. Cyst area and FAZ_DCP may serve as indicators of visual acuity in RP-CME.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.